Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07101666 · ClinicalTrials.gov registry record · Phase 2

Total Neoadjuvant Therapy With Short Course Radiation Therapy in Gastric Cancer

A Phase 2 study, sponsored by Washington University School of Medicine.

Not yet
Registry status
Phase 2
Development phase
20
Enrollment target

NCT07101666: Clinical Trial Phase 2 study, sponsored by Washington University School of Medicine.

NCT07101666 is a Phase 2 study that has not yet begun recruiting, run by Washington University School of Medicine. The registered enrollment target is 20 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (85% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07101666, a Phase 2 study, has not yet begun recruiting, sponsored by Washington University School of Medicine.

NOT YET RECRUITING
Registry status
Phase 2
Development phase
20 participants
Enrollment target

Study Summary

Standard treatment for patients with early stage gastric cancer consists of perioperative chemotherapy and surgical resection. If radiation therapy is administered in the adjuvant setting, the radiated area is often large and associated with significant toxicity. In this study, the investigators propose the addition of short course radiation therapy (SCRT) to chemotherapy in the neoadjuvant setting. The investigators hypothesize that this regimen of Total Neoadjuvant Therapy (TNT) will result in a higher rate of complete response (both pathologic and clinical), with less toxicity.

Primary Outcome

Complete response is defined as pathologic complete response (pCR) in operable patients and durable (1-year) clinical complete response (cCR) in medically inoperable patients. * pCR in operable patients is defined as no tumor on gastrectomy specimen. * Clinical complete response rate in inoperable patients is defined as having no evidence of disease on EUS and/or EGD and no definite evidence of disease on PET/CT.

Interventions

  • RADIATION Short course radiation therapy
  • DRUG Standard of care neoadjuvant chemotherapy

Trial Details

FieldValue
Enrollment Target 20 participants
Start Date 2026-06-30
Est. Completion 2030-12-31
Phase Phase 2

What is known before NCT07101666 opens enrollment

NCT07101666 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (85% lower).

The record links to 0 conditions, and to 2 interventions - of which Short course radiation therapy is the first listed.

NCT07101666 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT07101666 about?

NCT07101666 is a clinical study titled "Total Neoadjuvant Therapy With Short Course Radiation Therapy in Gastric Cancer". Standard treatment for patients with early stage gastric cancer consists of perioperative chemotherapy and surgical resection. If radiation therapy is administered in the adjuvant setting, the radiated area is often large and associated with significant toxicity. In this study, the investigators pr...

What is the current status of trial NCT07101666?

This trial is currently not yet recruiting. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2026-06-30. Estimated completion is 2030-12-31.

What interventions are being tested in trial NCT07101666?

The interventions under investigation include: Short course radiation therapy (RADIATION), Standard of care neoadjuvant chemotherapy (DRUG).

Who is sponsoring clinical trial NCT07101666?

This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT07101666's enrollment target sits among peer trials

20 1805th of 2000 higher than 107 of 2,000 other Phase 2 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00573339 · 20 participants

    Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing

  • NCT00692939 · 20 participants · Phase 1

    Autologous Stem Cell Transplantation for Crohn's Disease

  • NCT00967785 · 20 participants · Phase 1

    A Phase I Study of Mozobil in the Treatment of Patients With WHIMS

  • NCT01406691 · 20 participants · Phase 4

    Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT07101666, the US trial registry maintained by the National Library of Medicine. NCT07101666 (small enrollment · none site footprint · not yet recruiting) retrieved and formatted by PlainTrial, see methodology.